# Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALL

> **NCT00529360** · PHASE1,PHASE2 · COMPLETED · sponsor: **New York Medical College** · enrollment: 32 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Acute Myelogenous Leukemia

## Interventions

- **DRUG:** Clofarabine
- **DRUG:** Clofarabine

## Key facts

- **NCT ID:** NCT00529360
- **Lead sponsor:** New York Medical College
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2016-01
- **Final completion:** 2016-03
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2016-03-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00529360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00529360, "Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALL". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00529360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*